Drug intelligence / Profile preview

LM103

Development stage: Phase 2
Lead developer: Suzhou Lanma Medical Technology
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LM103 is an autologous tumor infiltrating lymphocyte (TIL) therapy derived from each patient's resected tumor tissue and expanded ex vivo before reinfusion. It works through immunologic cytotoxicity and T lymphocyte replacement mechanisms. The treatment regimen typically includes lymphodepletion with fludarabine and cyclophosphamide prior to TIL infusion, followed by IL-2 therapy, and in some protocols, combination with PD-1 inhibitors.

Other names: Autologous tumor infiltrating lymphocytes - Suzhou BlueHorse Therapeutics

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on LM103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM103.

Explore the full profile